Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial

Patients with inherited thrombocytopenias often require platelet transfusions to raise their platelet count before surgery or other invasive procedures; moreover, subjects with clinically significant spontaneous bleeding may benefit from an enduring improvement of thrombocytopenia. The hypothesis that thrombopoietin-mimetics can increase platelet count in inherited thrombocytopenias is appealing, but evidence is scarce. We conducted a prospective, phase II clinical trial to investigate the efficacy of the oral thrombopoietin-mimetic eltrombopag in different forms of inherited thrombocytopenia. We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia. The average pre-treatment platelet count was 40.4 ×109/L. Patients received a 3- to 6-week course of eltrombopag in a dose-escalated manner. Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 ×109/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond. The average increase of platelet count compared to baseline was 64.5 ×109/L (P<0.001). Four patients with clinically significant spontaneous bleeding entered a program of long-term eltrombopag administration (16 additional weeks): all of them obtained remission of mucosal hemorrhages, with the remission persisting throughout the treatment period. Treatment was globally well tolerated: five patients reported mild adverse events and one patient a moderate adverse event. In conclusion, eltrombopag was safe and effective in increasing platelet count and reducing bleeding symptoms in different forms of inherited thrombocytopenia. Despite these encouraging results, caution is recommended when using thrombopoietinmimetics in inherited thrombocytopenias predisposing to leukemia. ClinicalTrials.gov identifier: NCT02422394.

[1]  A. Verma,et al.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. , 2018, Blood.

[2]  Wendy N Erber,et al.  Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. , 2018, Blood advances.

[3]  C. Gachet,et al.  Inherited platelet disorders : Management of the bleeding risk. , 2018, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[4]  F. Rodeghiero,et al.  Thrombopoietin receptor agonists in hereditary thrombocytopenias , 2018, Journal of thrombosis and haemostasis : JTH.

[5]  P. Noris,et al.  Hereditary thrombocytopenias: a growing list of disorders. , 2017, Hematology. American Society of Hematology. Education Program.

[6]  J. Bussel,et al.  Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. , 2017, Blood.

[7]  G. Basso,et al.  Eltrombopag use in a patient with Wiskott–Aldrich syndrome , 2017, Pediatric blood & cancer.

[8]  P. Nurden,et al.  Bleeding risk of surgery and its prevention in patients with inherited platelet disorders , 2017, Haematologica.

[9]  F. Rodeghiero,et al.  Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists , 2017, Annals of Hematology.

[10]  A. Stamatoullas,et al.  Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. , 2017, The Lancet. Haematology.

[11]  M. Alessi,et al.  Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia , 2016, Platelets.

[12]  A. Pecci,et al.  Diagnosis and treatment of inherited thrombocytopenias , 2016, Clinical genetics.

[13]  K. Götze,et al.  Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. , 2015, The Lancet. Haematology.

[14]  M. Berny-Lang,et al.  Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. , 2015, Blood.

[15]  S. Kunishima,et al.  A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia , 2015, Annals of Hematology.

[16]  Benjamin Djulbegovic,et al.  Platelet Transfusion: A Clinical Practice Guideline From the AABB , 2015, Annals of Internal Medicine.

[17]  L. Alberio,et al.  Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis , 2014, Cytometry. Part B, Clinical cytometry.

[18]  W. Wiktor-Jedrzejczak,et al.  Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.

[19]  C. Balduini,et al.  Lessons in platelet production from inherited thrombocytopenias , 2014, British journal of haematology.

[20]  Paola Giordano,et al.  ANKRD26-related thrombocytopenia and myeloid malignancies. , 2013, Blood.

[21]  R. Favier,et al.  First Successful Use of Eltrombopag Before Surgery in a Child With MYH9-Related Thrombocytopenia , 2013, Pediatrics.

[22]  A. Savoia,et al.  Inherited thrombocytopenias frequently diagnosed in adults , 2013, Journal of thrombosis and haemostasis : JTH.

[23]  A. Pecci.  Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists , 2013, International Journal of Hematology.

[24]  R. Geha,et al.  Wiskott‐Aldrich syndrome: a comprehensive review , 2013, Annals of the New York Academy of Sciences.

[25]  P. Noris,et al.  Diagnosis and Management of Inherited Thrombocytopenias , 2013, Seminars in Thrombosis & Hemostasis.

[26]  C. Balduini,et al.  Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation , 2012, Thrombosis and Haemostasis.

[27]  A. Greinacher,et al.  A patient with Fechtner syndrome successfully treated with romiplostim , 2012, Thrombosis and Haemostasis.

[28]  P. Noris,et al.  Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation) , 2012, Haematologica.

[29]  P. Noris,et al.  Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. , 2011, Blood.

[30]  P. Noris,et al.  Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. , 2010, Blood.

[31]  A. Fischer,et al.  X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. , 2010, Blood.

[32]  P. Noris,et al.  Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families , 2009, Haematologica.

[33]  S. Watson,et al.  A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO , 2006, British journal of haematology.

[34]  A. Michelson.  Evaluation Of Platelet Function By Flow Cytometry , 2006, Pathophysiology of Haemostasis and Thrombosis.

[35]  Guidelines for the use of platelet transfusions , 2003, British journal of haematology.

[36]  A. Nagler,et al.  Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. , 2018, The Lancet. Haematology.

[37]  R. Favier,et al.  Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related Disease: A Case Report. , 2018, A&A practice.